An orally available drug, R406, and R788, a prodrug of R406, show antiarthritic effects in the collagen-induce arthritis animal model [105], and immunotherapy treatment of RA targeting activated macrophages where Syk is activated ameliorates the arthritic symptoms in an animal model [108]. Here, SYK is linked to arthritic joint disease.